Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Go back to Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 245.64 +6.08 (2.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $239.56 | 52 Week High | $109.10 | |||
| Open | $240.37 | 52 Week Low | $31.38 | |||
| Day High | $247.10 | P/E | N/A | |||
| Day Low | $237.97 | EPS | $-1.45 | |||
| Volume | 417,879 | |||||
